PSMA PET/CT for staging of prostate cancer requires optimal image quality, especially in the pelvis as primary area of interest for staging intermediate or high-risk primary prostate cancer and biochemical recurrent prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.